Cargando…
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
Somatic mutations in kinase genes are associated with sensitivity of solid tumors to kinase inhibitors, but patients with metastatic cancer eventually develop disease progression. In EGFR mutant lung cancer, modeling of acquired resistance (AR) with drug-sensitive cell lines has identified clinicall...
Autores principales: | Jia, Peilin, Jin, Hailing, Meador, Catherine B., Xia, Junfeng, Ohashi, Kadoaki, Liu, Lin, Pirazzoli, Valentina, Dahlman, Kimberly B., Politi, Katerina, Michor, Franziska, Zhao, Zhongming, Pao, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759720/ https://www.ncbi.nlm.nih.gov/pubmed/23733853 http://dx.doi.org/10.1101/gr.152322.112 |
Ejemplares similares
-
Evolutionary Modeling
of Combination Treatment Strategies To Overcome Resistance to Tyrosine
Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Mumenthaler, Shannon M., et al.
Publicado: (2011) -
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015) -
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015) -
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer
por: Chmielecki, Juliann, et al.
Publicado: (2010) -
Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)